TO: Health Care Providers
FROM: Mick Bolduc
Vaccine Coordinator-Connecticut Vaccine Program (CVP)
DATE: November 30, 2015
SUBJECT: DTaP/IPV/Hib (Pentacel®) vaccine supply

The primary purpose of this communication is to inform you of a temporary manufacturing delay of DTaP/IPV/Hib (Pentacel®) vaccine.

DTaP/IPV/Hib supply

The Centers for Disease Control & Prevention (CDC) has notified the Immunization Program of a temporary manufacturing delay of Sanofi Pasteur’s DTaP/IPV/Hib vaccine (brand name Pentacel®) that is expected to last throughout the first half of 2016. The delay will result in smaller quantities of Pentacel® available to the Connecticut Vaccine Program (CVP) to fill provider orders. We anticipate receiving approximately 70% of the Pentacel® that is normally distributed each month. Sanofi does have a sufficient supply of its single antigen vaccines (Daptacel, IPOL, and ActHib) to address the anticipated shortfall in Pentacel supply.

Providers have several options to address the delay:
- Increase order quantities for single antigen DTaP, IPV, and Hib vaccines to ensure there is enough vaccine to fully immunize children based on the recommended schedule;
- Order Glaxo SmithKline’s DTaP/IPV/Hepatitis B combination vaccine (brand name Pediarix®).

We recommend that providers who have started vaccinating a child with Pentacel® vaccine complete the series with Pentacel® whenever possible. Providers may want to consider using Pediarix® in infants who are just beginning their primary series in order to ensure there is sufficient vaccine for those infants who have already begun their primary series with Pentacel®.

Providers who place their orders directly through VTrckS must fax their Pentacel, Daptacel, IPOL, and ActHib orders to 860 509-8371 until the delay is resolved.

As always, if you have any questions, please feel free to contact me at (860) 509-7940.